The latest from
Truvian.

Jump To:

Press Releases | Media Coverage

Press Releases

October 1, 2026

Truvian Health announced a strategic alliance with Siemens Healthineers to advance the TruVerus™ platform and explore opportunities to expand access to high-quality blood testing.

January 21, 2026

FDA Clearance of CBC Marks a Defining Platform Milestone, Expanding TruVerus™ to 26 Cleared Assays and the first FDA clearance for CBC from a lithium heparin sample.

January 12, 2026

Truvian announced it has received 510(k) clearances from the U.S. FDA for nine additional analytes for TruVerus, the industry’s first FDA cleared multimodal benchtop blood analyzer.

January 7, 2026

Truvian announced the appointment of Michael J. Mina, MD, PhD as Chief Medical and Strategy Officer to oversee clinical and regulatory strategy, while advancing strategic partnerships and opportunities.

December 2, 2025

Truvian announced that the U.S. FDA has granted 510(k) clearance (K251058) for TruVerus™, the industry’s first multimodal blood testing benchtop instrument.

Media Coverage